Equillium (EQ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...

Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...

生物科技公司Equillium, Inc. (NASDAQ:EQ)，目前市值2,515万美元，股价0.71美元，今日宣布其用于治疗中重度溃疡性结肠炎(UC)的药物itolizumab二期临床试验取得积极结果。 根据InvestingPro数据显示，该公司资产负债表稳健，现金多于债务，但目前现金消耗速度较快。这项与Biocon Limited共同赞助的研究共纳入90名未使用过生物制剂的患者，随机分配 ...

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Meta’s recent “bonfire of safety measures” risks taking Facebook and Instagram back to where they were when Molly Russell died, the charity set up in her name has warned. The Molly Rose Foundation ...